<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584115</url>
  </required_header>
  <id_info>
    <org_study_id>6889</org_study_id>
    <secondary_id>CNPq 577582/2008-9</secondary_id>
    <nct_id>NCT01584115</nct_id>
  </id_info>
  <brief_title>Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)</brief_title>
  <official_title>Phase I Clinical Trial of a Therapeutic Vaccine for Malignancies, Comprising the Tumor Antigen NY-ESO-1 in Combination With the Adjuvant MPLA of Bordetella Pertussis. Evaluation of Toxicity and Immunogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigação em Imunologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigação em Imunologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability,
      immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined
      with the adjuvant MPLA from B. pertussis in cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety and immunogenicity of the vaccine with the antigen NY-ESO-1 in combination with
      the MPLA will be evaluated in a phase 1 clinical trial conducted in patients with
      malignancies that express the antigen (lung, ovarian and melanoma). This study will involve
      15 patients, who will receive 250 mcg of NY-ESO-1 and 100 mcg of MPLA.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Six months after immunization.</time_frame>
    <description>CTCAE (Common Terminology Criteria for Adverse Events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Six months after immunization.</time_frame>
    <description>IgG against NY-ESO-1 (ELISA). NY-ESO-1-specific T cells CD4+ and CD8+ (ELISPOT and FACs - flow citometry with tetramers).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cancer.</condition>
  <condition>Melanoma.</condition>
  <condition>Ovarian Cancer.</condition>
  <condition>Lung Cancer.</condition>
  <arm_group>
    <arm_group_label>NY-ESO-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NY-ESO-1 combined with MPLA vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 combined with MPLA</intervention_name>
    <description>Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).</description>
    <arm_group_label>NY-ESO-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 combined with MPLA vaccine</intervention_name>
    <description>Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine</description>
    <arm_group_label>NY-ESO-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In this study, will be included fifteen patients aged over 18 years, with a confirmed
             diagnosis of malignant neoplasms, which have proven NY-ESO-1 expression by
             immunohistochemistry and have undergone the standard treatment.

        Exclusion Criteria:

          -  Will be excluded from the study patients with continuous use of systemic steroids,
             immunosuppressive agents and antibiotics, and with severe chronic systemic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Giavina-Bianchi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Giavina-Bianchi, PhD,MD</last_name>
    <phone>(5511) 26616098</phone>
    <email>pbianchi@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcelo V Aun, MD</last_name>
    <phone>(5511) 26616225</phone>
    <email>marcelovivoloaun@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMUSP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigação em Imunologia</investigator_affiliation>
    <investigator_full_name>Pedro Giavina-Bianchi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer.</keyword>
  <keyword>Melanoma.</keyword>
  <keyword>Ovarian cancer.</keyword>
  <keyword>Lung cancer.</keyword>
  <keyword>NY-ESO-1.</keyword>
  <keyword>MPLA (monophosphoryl lipid A).</keyword>
  <keyword>Tumor antigen.</keyword>
  <keyword>Bordetella pertussis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Monophosphoryl lipid A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

